Optimizing R/R CLL Treatment: Therapy Sequencing and Supportive Care Strategies - Episode 2
Impact of Prior BTKi vs BCL2i Therapy on Treatment Decision-Making in CLL
Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.
Video content above is prompted by the following:
- How does the prior line of therapy (BTKi vs BCL2i) influence your treatment decision?
Related Content:
